Morningstar

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% - 52% with SBRT alone SBRT ...
FierceBiotech

IceCure's cryoablation treatment may extend survival in some lung cancer patients, study finds

Last month, IceCure Medical’s tumor-freezing technology won FDA approval for treating early-stage breast cancer. Now, the Israel-based medtech is touting a new study showing its procedure combined ...
Seeking Alpha

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

CAESAREA, Israel, Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (ICCM) (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that ...
Morningstar

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

This latest approval further broadens global access to ProSense® and supports IceCure's commercial momentum following the U.S. Food and Drug Administration's ("FDA") recent marketing authorization of ...
Medical News Today

What is cryoablation, and what does it treat?

Cryoablation involves applying extremely cold gas or liquid to an area of cancerous or abnormal tissue. The treatment freezes and destroys the cells. Doctors use cryoablation to treat tumors on the ...
Nasdaq

IceCure Medical Secures European Patent for Next-Generation Cryoablation Technology

Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Benzinga.com

Freezing Cancer With IceCure: ProSense Cryoablation System Receives FDA Marketing Authorization For Early-Stage Breast Cancer Treatment

IceCure Medical Ltd. (NASDAQ:ICCM), the developer of minimally invasive cryoablation technology that destroys tumors by freezing them, was granted marketing authorization from the U.S. Food and Drug ...
Nasdaq

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical ICCM recently announced that the company had submitted final data to the FDA requesting market authorization for its ProSense System. ProSense is designed to provide cryoablation, an ...